Risk of Orthopedic Surgical Site Infections in Patients with Rheumatoid Arthritis Treated with Antitumor Necrosis Factor Alfa Therapy by da Cunha, Bernardo Matos et al.
Hindawi Publishing Corporation
International Journal of Rheumatology
Volume 2012, Article ID 369565, 5 pages
doi:10.1155/2012/369565
Review Article
RiskofOrthopedicSurgical SiteInfectionsin
Patients with Rheumatoid Arthritis Treated with
Antitumor Necrosis Factor Alfa Therapy
BernardoMatosdaCunha,1 LiciaMariaHenriquedaMota,2
andLeopoldo LuizdosSantos-Neto3
1Department of Internal Medicine, Hospital SARAH Bras´ ılia, SARAH Network of Rehabilitation Hospitals,
SMHS Quadra 301 Bloco A, 70.335-901 Bras´ ılia-DF, Brazil
2Department of Rheumatology, University of Bras´ ılia, SGAN 605, Av. L2 Norte, 70840-901 Bras´ ılia-DF, Brazil
3Department of Internal Medicine, University of Bras´ ılia, SGAN 605, Av. L2 Norte, 70840-901 Bras´ ılia-DF, Brazil
Correspondence should be addressed to Bernardo Matos da Cunha, bmcunha@sarah.br
Received 27 October 2011; Accepted 15 December 2011
Academic Editor: Yehuda Shoenfeld
Copyright © 2012 Bernardo Matos da Cunha et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Introduction. International guidelines recommend interruption of anti-TNF medications in the perioperative period, but there
are no randomized trials to support such recommendation. Objectives. To study literature evidence assessing the risk of surgical
site infections in orthopedic surgery patients with RA using anti-TNF drugs, compared to untreated patients or those using
conventional DMARD. Methods.Systematicreviewofcohortstudiesisconcerningsurgicalsiteinfectionsinorthopedicprocedures
in patients with RA. Results. Three studies were selected. Only one was considered of high-quality, albeit with low statistical power.
The review resulted in inconclusive data, since the best quality study showed no signiﬁcant diﬀerences between groups, while
others showed increased risk of infections in patients using anti-TNF medications. Conclusion. It is unclear whether patients with
RA using anti-TNF medications are at increased risk of surgical site infections. Randomized controlled trials or new high quality
observational studies are needed to clarify the issue.
1.Introduction
Rheumatoid arthritis (RA) aﬀects between 0.2 and 1% of
brazilian population [1]. Twenty-ﬁve percent of RA patients
undergo some surgery for the treatment of orthopedic
sequelae after 22 years of followup [2]. Currently, most
patientswithRAareinuseofconventionalmodifyingdisease
activity drugs (DMARD), and some of them are on antago-
nists of tumor necrosis factor (anti-TNF) medications [3, 4].
Anti-TNF drugs have been used to treat patients with RA
who do not get to remission with one or more conventional
DMARD.Systematicreviewshaveshownnoincreasedriskof
bacterial infections after treatment with such drugs [5, 6].
There is no consensus in the literature on the use of
immunosuppressive drugs in the perioperative period in
orthopedic surgery since there are few studies on the topic.
A randomized clinical trial showed no increased periopera-
tive infections in patients on methotrexate [7]. There are no
clinical trials assessing treatment with anti-TNF medications
in this context so far. The guidelines of the American College
of Rheumatology (ACR), British Society of Rheumatology,
and Japan College of Rheumatology recommend the suspen-
sion of anti-TNF medications in the perioperative period
[8–10], but this might lead to worsening of disease activity,
which could aﬀect the postoperative rehabilitation.
In observational studies of patients undergoing hip and
knee arthroplasties, several independent risk factors for
surgical site infection were found, including RA itself, male
gender, age greater than or equal to 75 years, secondary
osteoarthritis, type of prosthesis, no cement prosthesis,
comorbidity index, joint injury by trauma, American Society
of Anesthesiology physical status classiﬁcation greater than2 International Journal of Rheumatology
or equal to 3, wound hematoma, days of wound drainage,
and surgical time, which is the most consistently described
risk factor [11–15].
The objective of this study was to perform a systematic
review of observational studies on the risk of surgical site
infections (SSI) in orthopedic surgery in patients with RA,
treatedwithanti-TNFdrugs,comparedtountreatedpatients
or those using conventional DMARD.
2. Methods
2.1. Types of Studies. Prospective or retrospective cohort
studies that assessed the risk of SSI in orthopedic surgery in
patients with RA, treated with anti-TNF drugs, compared to
untreatedpatientsorthoseusingconventionalDMARDwere
eligible. Studies could evaluate patients undergoing any type
of orthopedic surgery, including arthroplasty. The minimum
followup should be one year, so that all prosthetic infections
were accounted [16].
2.2. Types of Patients. RA patients are classiﬁed according to
ACR 1987 criteria [17].
2.3. Outcomes. Superﬁcial or deep incisional infections or
prosthesis infections, deﬁned by objective criteria.
2.4. Search Strategy. We used the following keywords: “anti-
tumor necrosis factor,” “DMARD,” “rheumatoid arthri-
tis”, “orthopedic surgery,” and “infection,” all simultane-
ously and in combinations between themselves. Search
was performed in the Cochrane Collaboration, MEDLINE,
EMBASE, CINAHL, and LILACS databases. We included
only those studies in English, Portuguese, and Spanish.
2.5. Data Collection and Analysis of Studies. After the search
results, the abstracts were initially assessed. After selecting
articles that met inclusion criteria, we performed a gen-
eral reading of the articles, followed by methodological
analysis. Data were collected in a systematic manner on
a standardized form. Initially, it was noted whether the
study was prospective or retrospective and whether there was
sample size calculation. Then, we applied Newcastle-Ottawa
Cohort Quality Assessment Scale [18], which has good
applicability for the purposes of this review. These criteria
split the analysis into three areas: selection, comparability,
and outcome. In each of these areas, we applied a number
of questions and, according to the answer, a “asterisk” is
attributed. In the ﬁelds “selection” and “outcome,” it is
possible to assign one “asterisk” for each question, while
it is possible to assign two “asterisks” to the question
“comparability.” We performed an adaptation to questions
so that they could apply to the scenario of this review.
The assessment details are shown in Table 1. Studies were
considered of high quality if they had at least one “asterisk”
in each area, and the sum of the “asterisks” were equal to
or greater than ﬁve.Due to heterogeneity of the studies, no
qualitative data analysis was performed.
Table 1: Newcastle-Ottawa Cohort Quality Assessment Scale,
adaptedforreviewpurposes,asdescriptionfromauthors.Acronym:
RA: rheumatoid arthritis.
Selection
(1) Representativeness of the exposed cohort
(a) truly representative of the average RA patient in the
community∗
(b) somewhat representative of the average RA patient in the
community∗
(c) selected group of users e.g., nurses, volunteers
(d) no description of the derivation of the cohort
(2) Selection of the nonexposed cohort
(a) drawn from the same community as the exposed cohort∗
(b) drawn from a diﬀerent source
(c) no description of the derivation of the nonexposed cohort
(3) Ascertainment of exposure
(a) secure record (e.g., surgical records)∗
(b) structured interview ∗
(c) written self-report
(d) no description
(4) Demonstration that outcome of interest was not present at start
of study
(a) yes∗
(b) no
Comparability
(1) Comparability of cohorts on the basis of the design or analysis
(a) study controls for surgical time∗
(b) study controls for any additional factor ∗
Outcome
(1) Assessment of outcome
(a) independent blind assessment∗
(b) record linkage∗
(c) self-report
(d) no description
(2) Was followup long enough for outcomes to occur?
(a) yes (1 year)
(b) no
(3) Adequacy of followup of cohorts
(a) complete follow up—all subjects accounted for∗
(b) subjects lost to followup unlikely to introduce bias—small
number lost—>80% follow up, or description provided of those
lost∗
(c) followup rate < 80% and no description of those lost
(d) no statement
∗Studies were considered of high quality if they had at least one asterisk in
each area, and the sum of the asterisks were equal to or greater than ﬁve.
3. Results
3.1. Search. Initially 283 abstracts were found in MEDLINE.
Search in other databases did not add additional abstracts.
Six abstracts were selected according to inclusion criteriaInternational Journal of Rheumatology 3
and, after general manuscript reading, three studies [19–
21] were included in the review. Details of articles selection
are shown in Figure 1. Since we selected few articles, it was
possible to describe each one separately.
3.2. Description of Studies. Studies included 1767 proce-
dures. The study by Momohara et al. was not clear about the
number of of patients, so was not possible to express their
exact number.
The study by den Broeder et al. [19]i sar e t r o s p e c t i v e
cohort that included 1219 patients in 768 procedures from
two centers in the Netherlands. Its population consisted of
patients who underwent various types of orthopedic surgery
between 2001 and 2004. Procedures were excluded if the
time from the last procedure was less than three months.
Patients were divided into two groups: those who were on
anti-TNF therapy (cohort 2) versus those who had never
used these medications (cohort 1), but it was not clear
which DMARD they were in use. The ﬁrst group was then
divided into two groups: patients who were in use of anti-
TNF therapy in the perioperative period (cohort 2b) versus
those who had discontinued the drug at least four half-lives
before the surgery (cohort 2a). In cohort 2, patients were
being treated with inﬂiximab in 80 procedures, etanercept
in 79, and adalimumab in 37 procedures. In addition to the
primary outcome, this study also evaluated the incidence
of wound dehiscence, bleeding or hematoma, subluxation,
reoperation, and death. The rate of SSI in cohorts 1, 2ł, and
2b was 4.0%, 5.8% and 8.7%, respectively. No increased risk
of SSI was found in cohort 2, compared to cohort 1. In this
comparison, odds ratio (OR) values and conﬁdence intervals
(CI) were not provided and were calculated by the main
author of this review (OR 1.84, 95% CI 0.98 to 3.44). The
comparison between the cohorts 2a and 2b showed similar
numbers of SSI between groups (OR 1.56, 95% CI 0.52 to
4.66). Regarding the “wound dehiscence” outcome, there
was an increased incidence in patients who continued using
the anti-TNF compared with those who had stopped (OR
11.2, 95% CI 1.4 to 90). Comparsion between patients on
anti-TNF therapy who discontinued the drug and patients
who were anti-TNF naive showed a reduced incidence in the
former group (OR 2.4, 95% CI 1.1 to 5.0). There were no
data on disease activity.
The study by Kawakami et al. [20]i sar e t r o s p e c -
tive cohort that included 128 procedures in 112 patients
from a single center in Japan. The population consisted
of patients undergoing joint surgery between 2004 and
2009, in which most of them were arthroplasties. A 1:1
matching was performed among patients receiving anti-TNF
versus conventional DMARD. In the group on anti-TNF
therapy, patients were taking inﬂiximab in 35 surgeries and
etanerceptin29surgeries.PatientsonconventionalDMARD
were using methotrexate in 48 cases, sulfasalazine in 18
cases, bucillamine (an immunomodulator drug developed
in Japan, similar to D-penicillamine) in 6 cases, and D-
penicillamine in 4 cases, either alone or in combination. In
addition to the primary outcome, the presence of arthralgia
and deep vein thrombosis (DVT) diagnosed with ultra-
sonography was assessed, but without specifying whether
Search in Cochrane, 
MEDLINE, EMBASE, CINAHL, and 
LILACS: 283 abstracts
Selected for general reading:
6  manuscripts
methodological analysis:
3 studies
Excluded: 3 studies
RA case deﬁnition without 
1987 ACR criteria: 2 
Different outcome from the 
one assessed in the review: 1
Selected for
Figure 1: Fluxogram of studies selection. Acronyms: RA: rheuma-
toid arthritis; ACR: American College of Rheumatology.
tests were performed in all patients. Anti-TNF medications
were discontinued 2–4 weeks before surgery and it is unclear
if conventional DMARD were also discontinued. OR and
CI were not provided and were calculated by the main
author based on information collected in the study. The
SSI rate was higher among patients on anti-TNF therapy
thaninpatientsreceivingconventionalDMARD(12.5% and
1.6% resp.) (OR 9.0, 95% CI 1.1–74.22). The incidence
of DVT was higher among patients on anti-TNF therapy
than in patients receiving conventional DMARD (OR 2.9,
95% CI 1.2 to 6.9). Regarding the outcome “arthralgia,”
comparisons were made only within the group of patients
treated with anti-TNF medications.The study of Momohara
et al. [21]i sar e t r o s p e c t i v ea n a l y s i so fap r o s p e c t i v e
cohort that included 420 procedures performed by the
same group of Kawakami et al. The population consisted
of patients undergoing hip (81 cases) and knee (339 cases)
arthroplasties between 2005 and 2009. Initially, the authors
divided patients into two groups: individuals on anti-TNF
therapy versus those using conventional DMARD. However,
when reporting the results, the authors have chosen to make
comparisons according to the outcome, setting a nested
case-control design. As the study provided the data for
each group, it was possible to calculate OR and CI for
the comparison according to the risk factor. In the group
of patients using anti-TNF medications, 19 patients were
treated with inﬂiximab, 23 with etanercept, and 2 with
adalimumab. In the group of patients using conventional
DMARDs, 279 patients were treated with methotrexate, 93
withsulfasalazine,52withbucillamine,7withminocycline,4
with leﬂunomide, 31 with tacrolimus, 15 with mizoribine (a
drug with immunomodulatory mechanism of action similar
to mycophenolate mofetil), 3 with cyclophosphamide, 9 with
actarit (an immunomodulator drug developed in Japan, a
nitric oxide inhibitor), 4 with auranoﬁn, 1 patient with
aurothiomalate, and 16 patients with D-penicillamine, alone
or in combination. Conventional DMARD were kept during4 International Journal of Rheumatology
Table 2: Quality of studies according to Newcastle-Ottawa Cohort Quality Assessment Scale.
Studies Selection Comparability Outcome Total Quality
den Broeder AA e cols. ∗∗∗∗ ∗∗ ∗∗∗ 9 high
Kawakami K e cols. ∗∗∗∗ 4l o w
Momohara S e cols. ∗∗∗∗ 4l o w
∗Studies were considered of high quality if they had at least one asterisk in each area, and the sum of the asterisks were equal to or greater than ﬁve.
the perioperative period, and anti-TNF medications were
discontinued 2–4 weeks before surgery. The SSI rate was
higher among patients using anti-TNF than in patients
receivingconventionalDMARD(20.8%and4.0%resp.)(OR
6.3,95%CI2.6to149).Mostinfectionsweresuperﬁcial,and
there was no data on disease activity.
3.3. Quality Rating. The only study considered of high qual-
ity by our assessment was AA den Broeder et al. (Table 2).
It was also the only study that included patients receiving
adalimumabandassessedallocationbias.However,thestudy
did not achieve suﬃcient statistical power to detect small
diﬀerences. A post hoc calculation of statistical power of this
study was 49.4%. The other two studies showed several
methodological ﬂaws and heterogeneous methodologies,
which hampered the statistical analysis between groups with
and without the use of anti-TNF medications, including
logistic regression, so it is likely to have occurred association
bias. On the other hand, in these studies, anti-TNF medi-
cations were discontinued 2–4 weeks before surgery, which
may have diminished the risk of infections with such drugs.
As followup was not informed, it is not clear whether all
infections were recorded. There was no information about
the frequency of progression to deep infections.
4. Discussion
Currently, there are no randomized trials that have assessed
safety of anti-TNF medications in the orthopedic surgery
perioperative period. The available body of evidence is
basedonobservationalstudiesandexpertopinion.Although
some international guidelines recommend discontinuation
of medications before surgery, according to drug half-life [6–
8], the results of this review indicate that there is insuﬃcient
evidence to support these recommendations. Two Japanese
studies, performed by the same group, have shown signiﬁ-
cantly increased risk of surgical site infections in patients on
anti-TNF therapy when compared to patients using conven-
tional DMARD, but it is not clear if both studies included
some patients in common. In contrast, the single high
quality study (den Broeder AA et al.), performed in another
ethnic group, showed no increased risk of infections.
Moreover, it was the only study that compared anti-TNF
na¨ ıve patients to the ones in current treatment with anti-
TNF medications and to others who discontinued the
anti-TNF drugs before surgery, including patients receiving
adalimumab. It was also the only study to describe follow-up
time. Unfortunately, this study had a low statistical power,
probablybecausetheestimatednumberofinfectionswasless
than expected. In the Japanese studies, anti-TNF drugs were
discontinued in the perioperative period, not allowing the
observation of outcomes in the presence of full serum levels
of the analyzed drugs.
On the other hand, none of the studies properly assessed
disease activity. Discontinuation of immunomodulatory
treatment may allow the reactivation of joint inﬂammatory
activity in the perioperative period, what can lead to
diﬃculties in the rehabilitation process.
In conclusion, it is not clear, according to the body
of evidence currently available, whether patients with RA
using anti-TNF medications are at increased risk of surgical
site infections, compared to patients receiving conventional
DMARD. Multicenter randomized controlled trials or new
prospective high quality observational studies are needed
to make it possible to reach a ﬁrm conclusion, including
patients from distinct ethnicities, with suﬃciently numerous
population and assessing adalimumab use. For now, we
recommend that discontinuation of anti-TNF drugs should
occur after a case-based discussion between clinicians and
surgeons, considering the risks and beneﬁts, taking into
account patient characteristics, the intended procedure and
the institution where the surgery will be performed.
Conﬂict of Interests
The authors declare that there is no conﬂict of interests.
Acknowledgment
Thanks are due to S´ ergio Henrique Rodolpho Ramalho for
helping in translation to english.
References
[ 1 ]J .F .M a r q u e sN e t o ,E .T .G o n c ¸alves, L. Langen et al., “Estudo
multicˆ entrico da prevalˆ encia da artrite reumat´ oide do adulto
em amostras da populac ¸˜ ao brasileira,” Revista Brasileira de
Reumatologia, vol. 33, no. 5, pp. 169–173, 2002.
[2] D. A. Pappas and J. T. Giles, “Do antitumor necrosis factor
agents increase the risk of postoperative orthopedic infec-
tions?” Current Opinion in Rheumatology,v o l .2 0 ,n o .4 ,p p .
450–456, 2008.
[3] “Registro Brasileiro de Monitorizac ¸˜ ao de Terapias Biol´ ogicas
em Doenc ¸as Reum´ aticas BIOBADABRASIL. Biobadamerica,”
http://biobadaser.ser.es/biobadamerica/Brasil/cgi-bin/upload/
documentacion.aspx.
[4] J. R. Curtis, A. Jain, J. Askling et al., “A comparison of
patient characteristics and outcomes in selected european and
U.S. rheumatoid arthritis registries,” Seminars in Arthritis and
Rheumatism, vol. 40, no. 1, pp. 2–14.e1, 2010.
[5] A. E. Thompson, S. W. Rieder, and J. E. Pope, “TNF
therapy and the risk of serious infection and malignancy inInternational Journal of Rheumatology 5
patients with early rheumatoid arthritis: a meta-analysis of
randomized controlled trials,” Arthritis and Rheumatism, vol.
63, no. 6, pp. 1479–1485, 2011.
[6] J. P. Leombruno, T. R. Einarson, and E. C. Keystone, “The
safety of anti-tumour necrosis factor treatments in rheuma-
toid arthritis: meta and exposure-adjusted pooled analyses of
serious adverse events,” Annals of the Rheumatic Diseases, vol.
68, no. 7, pp. 1136–1145, 2009.
[ 7 ] D .M .G r e n n a n ,J .G r a y ,J .L o u d o n ,a n dS .F e a r ,“ M e t h o t r e x a t e
and early postoperative complications in patients with
rheumatoid arthritis undergoing elective orthopaedic
surgery,” Annals of the Rheumatic Diseases, vol. 60, no. 3, pp.
214–217, 2001.
[ 8 ]K .G .S a a g ,G .G .T e n g ,N .M .P a t k a re ta l . ,“ A m e r i c a n
College of Rheumatology 2008 recommendations for the use
of nonbiologic and biologic disease-modifying antirheumatic
drugs in rheumatoid arthritis,” Arthritis & Rheumatism, vol.
59, no. 6, pp. 762–784, 2008.
[9] J. Ledingham and C. Deighton, “Update on the British
Society for Rheumatology guidelines for prescribing TNF-
α blockers in adults with rheumatoid arthritis (update of
previous guidelines of April 2001),” Rheumatology, vol. 44, no.
2, pp. 157–163, 2005.
[10] R. Koike, T. Takeuchi, K. Eguchi, and N. Miyasaka, “Update
on the Japanese guidelines for the use of inﬂiximab and
etanercept in rheumatoid arthritis,” Modern Rheumatology,
vol. 17, no. 6, pp. 451–458, 2007.
[11] E. J¨ amsen, H. Huhtala, T. Puolakka, and T. Moilanen, “Risk
factors for infection after knee arthroplasty. A register-based
analysis of 43,149 cases,” Journal of Bone and Joint Surgery, vol.
91, no. 1, pp. 38–47, 2009.
[12] K. L. Ong, S. M. Kurtz, E. Lau, K. J. Bozic, D. J. Berry,
and J. Parvizi, “Prosthetic joint infection risk after total
hip arthroplasty in the medicare population,” Journal of
Arthroplasty, vol. 24, no. 6, pp. 105–109, 2009.
[13] S. Ridgeway, J. Wilson, A. Charlet, G. Katafos, A. Pearson, and
R. Coello, “Infection of the surgical site after arthroplasty of
the hip,” Journal of Bone and Joint Surgery,v o l .8 7 ,n o .6 ,p p .
844–850, 2005.
[14] K. Saleh, M. Olson, S. Resig et al., “Predictors of wound
infection in hip and knee joint replacement: results from a 20
year surveillance program,” Journal of Orthopaedic Research,
vol. 20, no. 3, pp. 506–515, 2002.
[15] D. M. Urquhart, F. S. Hanna, S. L. Brennan et al., “Incidence
and risk factors for deep surgical site infection after primary
total hip arthroplasty: a systematic review,” Journal of Arthro-
plasty, vol. 25, no. 8, pp. 1216–1222, 2010.
[16] Deﬁnic ¸˜ ao dos crit´ erios nacionais de infecc ¸˜ oes relacionadas
` a assistˆ encia ` as a ´ ude: prevenc ¸˜ ao de infecc ¸˜ oes do s´ ıtio
cir´ urgico (ISC). Agˆ encia Nacional de Vigilˆ ancia Sanit´ aria
http://www.anvisa.gov.br/servicosaude/manuais/index.htm.
[17] F.C.Arnett,S.M.Edworthy,D.A.Blochet al.,“TheAmerican
Rheumatism Association 1987 revised criteria for the classiﬁ-
cation of rheumatoid arthritis,” ArthritisandRheumatism,vol.
31, no. 3, pp. 315–324, 1988.
[18] G.A.Wells,B.Shea,D.O’Connelletal.,TheNewcastle-Ottawa
Scale (NOS) for Assessingthe Quality of Nonrandomised Studies
in Meta-analyses, Ottawa Hospital Research Institute, Ottawa,
Canada, 2010.
[ 1 9 ]A .A .d e nB r o e d e r ,M .C .C r e e m e r s ,J .F r a n s e ne ta l . ,“ R i s k
factors for surgical site infections and other complications
in elective surgery in patients with rheumatoid arthritis
with special attention for anti-tumor necrosis factor: a large
retrospective study,” Journal of Rheumatology, vol. 34, no. 4,
pp. 689–695, 2007.
[20] K. Kawakami, K. Ikari, K. Kawamura et al., “Complications
and features after joint surgery in rheumatoid arthritis
patients treated with tumour necrosis factor-α blockers: peri-
operative interruption of tumour necrosis factor-α blockers
decreases complications?” Rheumatology, vol. 49, no. 2, pp.
341–347, 2010.
[21] S. Momohara, K. Kawakami, T. Iwamoto et al., “Prosthetic
joint infection after total hip or knee arthroplasty in rheuma-
toid arthritis patients treated with nonbiologic and biologic
disease-modifying antirheumatic drugs,” Modern Rheumatol-
ogy, vol. 21, no. 5, pp. 469–475, 2011.